Shots:

• KaliVir to receive $56M as upfront & other payments supporting the research & preclinical activities of VET2-L2 & is eligible to receive $307M & $271M as development- regulatory & commercialization for VET2-L2 & second product- respectively along with royalties on sales of each licensed product
• The alliance integrates KaliVir's expertise in the development of oncolytic viruses with Astellas' capabilities in advanced drug development & its global business experience- enabling both parties to develop new immuno-oncology therapies
• VET2-L2 (IV) is an oncolytic vaccinia virus that destroys cancer cells & activates anti-cancer immunity through the expression of therapeutic transgenes

 ­ Ref: PRNewswire | Image: BioSpectrum Asia